Insights

A technical deep dive for professionals who need more than a checklist. This is the architecture of a market-winning generic […]

For pharma IP teams, portfolio managers, R&D leads, and institutional investors tracking the $72B biosimilar market. 1. Executive Summary and

The U.S. healthcare system has already saved an estimated $23.6 billion from biosimilar use [1]. Yet for all that money

Generic drug development sits at the intersection of two disciplines that most organizations still treat as separate workstreams: intellectual property

A $2.23 billion bet on a molecule. A 90% chance it never reaches a patient. A 20-year patent clock that

Introduction: The Decision That Happens Before Anyone Is Watching The pharmaceutical industry runs on headline milestones. The Phase III readout.

Part I: The Strategic and Financial Imperative of FTO The $2.6 Billion Bet and the One Analysis That Protects It

1. Why Drug Naming Is an IP Function, Not a Marketing Task The name on the bottle is not chosen

Part I: The Economic Architecture of Pharmaceutical Intellectual Property 1.1 The Patent Bargain and Its Financial Consequences The pharmaceutical industry